Articles tagged with: Carfilzomib
The 51st annual meeting of the American Society of Clinical Oncology (ASCO) started earlier today, May 29, and will go through June 2 in Chicago.
Approximately 30,000 physicians and researchers from all over the world are expected to attend the five-day meeting to discuss current research in cancer treatment and care.
During the meeting, there will be presentations about all types of cancer, including many presentations focused specifically on multiple myeloma. In fact, more than 90 myeloma-related studies are scheduled to be presented, in one form or another, in connection …
The results of a small Phase 1/2 clinical trial suggest that a combination of Farydak and high-dose Kyprolis is effective as a treatment for relapsed multiple myeloma.
Participants in the trial were heavily pretreated, having had a median of five previous myeloma therapies. More than 70 percent of the patients, however, had at least a partial response to the trial regimen at the target doses established during the trial’s first phase. The estimated two-year overall survival rate among the patients was 67 percent.
A response rate of more than 70 …
Initial results of a large, head-to-head clinical trial show that relapsed myeloma patients treated with high-dose Kyprolis and dexamethasone had twice the progression-free survival of relapsed patients treated with Velcade and dexamethasone.
Median progression-free survival in the Phase 3 trial was 18.7 months in trial participants treated with high-dose Kyprolis (carfilzomib) and dexamethasone (Decadron), compared to 9.4 months in patients treated with Velcade (bortezomib) and dexamethasone.
The results of the so-called “ENDEAVOR” trial were announced this past Sunday evening in a press release issued …
A new year is upon us. I hope it has started well for everybody, and that all had a great holiday season!
The last few weeks of 2014 were a happening time for the multiple myeloma community. The short span of time witnessed the publication of updated criteria for the diagnosis of multiple myeloma from the International Myeloma Working Group (IMWG). In addition, the 56th annual meeting of the American Society of Hematology (ASH) took place in San Francisco, with literally hundreds of myeloma-related oral and poster presentations.
Therefore, it …
This past Sunday was the second day of the American Society of Hematology’s (ASH) annual meeting, which was held in San Francisco.
As on the first day of the meeting, myeloma-related presentations once again took place during several sessions throughout the day.
A myeloma-related education session held the first day of the conference was repeated once again on Sunday morning.
While the education session was being held, a separate “scientific symposium” with two oral presentations took place in parallel. The session focused on a novel immunotherapeutic approach to treating cancer …